Making progress in treating glioblastoma
By Jennifer O'Hara
When it comes to malignant tumors in the brain and spinal cord, glioblastoma is the most common. Glioblastoma is an aggressive form of cancer that forms from cells called astrocytes in the brain or the spinal cord. Glioblastoma can occur at any age, but it's more common in older adults. It can cause worsening headaches, nausea, vomiting and seizures.
Glioblastoma can be difficult to treat. Current treatments include surgery, radiation and chemotherapy, but thanks to research and clinical trials, new therapies are being developed.
"We're coming together as a community to treat this," says Wendy Sherman, M.D., a Mayo Clinic neurologist. "We're getting more patients on trial and we're being smarter about our trials. It's an exciting time for our field, and I'm very hopeful that we're going to make progress on this."
A cure is often not possible, but disease management and treatment may slow progression of the cancer and decrease the side effects.
Watch Dr. Sherman discuss glioblastoma diagnosis, treatment and research in this "Mayo Clinic Q&A" podcast video:
____________________________________________
For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was either recorded prior to COVID-19 or recorded in a nonpatient care area where social distancing and other safety protocols were followed.
Learn more
Learn more about glioblastoma and find a glioblastoma clinical trial at Mayo Clinic.
Also read these articles:
- "Brain tumors: What you should know."
- "Glioblastoma in older adults: improving survival and quality of life."
- "Complex brain surgery gives woman more time with family."
- "New therapies, holistic modalities and hope help photographer see future."
A version of this article was originally published on the Mayo Clinic News Network.
Related Posts
Dr. Rich Byrne, a Mayo Clinic neurosurgeon, explains how brain tumors are classified and what that means for treatment.
Findings show extended progression-free survival for people with meningiomas who received a radiopharmaceutical approved for neuroendocrine tumors.
Mayo Clinic study findings reveal a protein that increases glioblastoma malignancy, a new understanding of the tumor's biology, and a potential new treatment strategy.